Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.48 |
| ▸ | DRD2 | P14416 | 7/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468606 | 0.98 | DRD2 (0.47) | HTR1ADRD2HTR2AADRA1DHTR1B | |
| SCHEMBL5468162 | 0.96 | HTR1A (0.42) | HTR1ADRD2HTR2AADRA1DHTR1B | |
| SCHEMBL5470435 | 0.87 | HTR1A (0.48) | HTR1ADRD2HTR2AADRA1DHTR1B | |
| SCHEMBL5471383 | 0.84 | DRD2 (0.48) | HTR1ADRD2HTR2AADRA1DHTR1B | |
| SCHEMBL5461977 | 0.84 | DRD2 (0.47) | HTR1ADRD2HTR2AADRA1DHTR1B | |
| SCHEMBL5461985 | 0.82 | DRD2 (0.44) | HTR1ADRD2HTR2AADRA1A | |
| SCHEMBL5468095 | 0.82 | HTR1A (0.43) | HTR1ADRD2HTR2AADRA1DHTR1B | |
| SCHEMBL5479077 | 0.82 | DRD2 (0.50) | HTR1ADRD2HTR2AADRA1AHTR7 | |
| SCHEMBL5463279 | 0.82 | DRD2 (0.48) | HTR1ADRD2HTR2AADRA1AHTR7 | |
| SCHEMBL5473542 | 0.81 | DRD2 (0.46) | HTR1ADRD2HTR2AADRA1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299091-A1 | Azaindole Carboxamides | GMEINER PETER | 2007-12-27 | — | — | US | claimed |
| US-20070299091-A1 | Azaindole Carboxamides | GMEINER PETER | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299091-A1 | Azaindole Carboxamides | TPH1, TPH2, HTR1A | HTR1A 3/4885DRD2 64/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.